SAN DIEGO, Aug. 1, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product was selected as one of the top ten podiatry innovations in 2012 by the publication Podiatry Today. The Company also announced that it will be introducing Excellagen at the American Podiatric Medical Association (APMA) National Meeting (Booth 1910) being held August 16 – 19, 2012 in Washington, DC.
The report, entitled "The Top 10 Innovations in Podiatry," states that Excellagen, "A new topical gel may help foster improved healing in chronic wounds." It is noted that "the product's full-length collagen molecules are in their natural, fibrillar form, and are formulated in a unique physiologic buffer that ensures maintenance of the collagen molecule's structure and function," as stated by Arthur Tallis, DPM, a Fellow of the American Professional Wound Care Association and the American College of Foot and Ankle Surgeons, who was a clinical investigator in the multi-center Phase 2b MATRIX study. The article can be viewed online at http://www.podiatrytoday.com/top-10-innovations-podiatry?page=3 and will appear in the August 2012 print issue of Podiatry Today.
As reported by Podiatry Today, "Dr. Tallis has applied Excellagen following surgical debridement in the presence of blood cells and platelets," and noted that "Excellagen activates human platelets, triggering the release of platelet-derived growth factors (PDGF)." With regard to the practice of podiatry and patient compliance, it was noted that "Excellagen can save time for the physician and patient as dressing changes are required only once a week." In terms of ease of application and use, it was stated that "additional advantages of Excellagen are that no thawing or mixing of components is required prior to use," and that "one can easily apply the formulation to wounds of all sizes and shapes, and the product achieves complete, even wound coverage without dripping."About Excellagen Excellagen is an FDA-cleared highly-purified formulated collagen topical gel (2.6%) engineered for debridement and platelet activation and to support a favorable wound healing environment for non-healing lower extremity diabetic ulcers and other dermal wounds. Excellagen's unique high-molecular weight structured collagen formulation is topically applied through easy-to-control, pre-filled, sterile, single use syringes and its viscosity-optimized gel formulation is designed for application at only one or two week intervals. Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors. Following FDA clearance, Cardium conducted additional studies showing that Excellagen can activate platelets to trigger the release of Platelet-Derived Growth Factor (PDGF), which is recognized as an important wound healing facilitator.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV